World Journal of Biochemistry and Molecular Biology  
Manuscript Information
Prevalence of Dyslipidemia and Its Associated Risk Factors Among Diabetic Patients Attending Muhima District Hospital, Kigali City, Rwanda
World Journal of Biochemistry and Molecular Biology
Vol.3 , No. 2, Publication Date: Jun. 13, 2018, Page: 66-71
3492 Views Since June 13, 2018, 778 Downloads Since Jun. 13, 2018

Jean Baptiste Niyibizi, Mount Kenya University, department of Medical Laboratory Sciences, Kigali, Rwanda; University of Gitwe, department of Medical Laboratory Technology, Nyanza, Rwanda; Kibogora Polytechnic, department of Biomedical Laboratory Sciences, Nyamasheke, Rwanda.


Maxime Mutangana, University of Gitwe, department of Medical Laboratory Technology, Nyanza, Rwanda.


Nadine Uwase, University of Gitwe, department of Medical Laboratory Technology, Nyanza, Rwanda.


Innocent Ndagijimana, Muhima Hospital, department of Non Communicable Diseases, Kigali, Rwanda.


Dyslipidemia is the most important independent predictor of cardiovascular diseases in diabetic patients. The risk of cardiovascular heart diseases in hyperglycemic patients is two to four times more as compare to normal. Although many researches revealed the prevalence and associated risk factors of dyslipidemia in diabetic patients across the world, this information is not well known in Rwanda, hence the need to carry out this research. The main objective of this study was to determine the prevalence of dyslipidemia and its associated risk factors in diabetic patients. The present was a cross-sectional study carried out at Muhima district hospital from February to April 2018. This study was conducted in 100 patients where males were 38 while females were 62. Men were seen less exposed to dyslipidemia with 15.78% versus 22.58% for women. Some other risk factors associated with dyslipidemia were intake of fatty diet with 91.6% of dyslipidemia; overweight (31.25%), history of diabetes (31.81%); obesity (12.50%) and physical exercises (15.78%). There was 28% of patients who had poor control of their blood glucose level (having HBA1C level greater than 7%), while 62% had a good blood glucose management with the HBA1C level of less than 7%.


Dyslipidemia, Diabetes, Risk Factors


American Diabetes Association. (2016). Classification and diagnosis of diabetes, diabetes care. 39 (Suppl. 1): S13-S22.


Amine E, Baba N, Belhadj M, Deurenbery-Yap M, Djazayery A, Forrester T, et. al. (2002). Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO Expert consultation. World Health Organization.


Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ.(2017). Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 Sep 28; 377 (13): 1217-1227.


Chattanda SP, & Mgonda YM. (2008). Diabetic Dyslipidemia Among Diabetic Patients Attending Specialized Clinics in Dar es Salaam. Tanzania Medical Journal 23 (1): 8-11. Doi: 10.4314/tmj.v23i1.39221


Christenson, R. H., Gregor, L. C. and Johnson, L. J. (2001) Appleton & Lange’s Outline Review. Clinical Chemistry, McGraw-Hill Companies, New York, Chicago, Lisbon, Madrid.


Djelilovic-Vranic J, Alajbegovic A, Zelija-Asimi V, Niksic M, Tiric-Campara M, Salcic S, Celo A. (2013). Predilection role diabetes mellitus and dyslipidemia in the onset of ischemic stroke. Med. Arch, 67, 120–123.


Isezuo SA, & Ezunu E. (2005). Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. Journal of the National Medical Association. 97 (4): 557-563.


Jayarama, N.; Lakshmaiah, M. R. (2011). Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India. Glob. J. Med. Public Health 2012, 1, 24–27.


Kennady AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. (2005). The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 28: 1029–34.


Jennifer Nicholas, Judith Charlton, Alex Dregan, and Martin C. Gulliford (2013). Recent HBA1C Values and Mortality Risk in Type 2 Diabetes. Population-Based Case-Control Study. PLoS One. 2013; 8 (7).


Konstantinos Papatheodorou, Maciej Banach, Michael Edmonds, Nikolaos Papanas, and Dimitrios Papazoglou. (2016). Complications of Diabetes. Journal of Diabetes Research. Volume 2015, 189525.


National center for Biotechnology Institute. (2009). Classification of dyslipidemia. Retrieved from on 22nd April 2018.


National Institutes of Health. (2012). Cholesterol levels. Retrieved from On 14/05/2018


Odebunmi E O, Owalude, S O.(2007). Kinetic and thermodynamic studies of glucose oxidase catalysed oxidation reaction of glucose. J. Appl. Sci. Environ. Manage 11 (4) 95–100.


Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y.(2015). Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. Int J Environ Res Public Health. 26; 12 (10): 13455-65.


Rwanda diabetes associations. (2016). Diabetes in Rwanda. Retrieved from on 23rd February 2018.


Rader (2007). Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 120 (3): 12-8.


SurveyMonkey. 2018. Sample Size Calculator. Retrieved from On 2nd Jan 2018.


Sang Victor Kiplagat, Kaduka Lydia, Kamano Jemimah and Makworo Drusilla. (2017). Prevalence of Dyslipidemia and The Associated Factors Among Type 2 Diabetes Patients in Turbo Sub- County, Kenya. J Endocrinol Diab 4 (5): 1-9.


Vaneeta Bamba (2014). Update on Screening, Etiology, and Treatment of Dyslipidemia in Children. J Clin Endocrinol Metab, 99 (9): 3093–3102.


World Health Organization. Non communicable Diseases Country Profiles. 2014 (91–93); Genève: WHO Press.

  Join Us
  Join as Reviewer
  Join Editorial Board